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Ebola virus disease (EVD) has mostly affected economically deprived countries as limited resources adversely affect
a country’s infrastructure and administration. Probing into the factors that led to the widespread outbreak, setting
forth plans to counter EVD cases in developing countries, and devising definitive measures to limit the spread of
the disease are essential steps that must be immediately taken. In this review we summarize the pathogenesis of
EVD and the factors that led to its spread. We also highlight interventions employed by certain countries that have
successfully limited the epidemic, and add a few preventive measures after studying the current data. According
to the available data, barriers to prevent and control the disease in affected countries include irresolute and
disorganized health systems, substandard sanitary conditions, poor personal hygiene practices, and false beliefs and
stigma related to EVD. The public health sector along with the respective chief authorities in developing countries
must devise strategies, keeping the available resources in mind, to deal with the outbreak before it occurs. As a
first step, communities should be educated on EVD’s symptoms, history, mode of transmission, and methods of
protection, including the importance of personal hygiene practices, via seminars, newspapers, and other social
media. A popular opinion leader (POL) giving this information would further help to remove the misconception
about the nature of the disease and indirectly improve the quality of life of affected patients and their families.
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The first Ebola virus disease (EVD) outbreak occurred
simultaneously in Nzara, Sudan (involving 281 patients
out of which 151 died [54%]) [1] and Yambuku, Zaire
(now the Democratic Republic of Congo) (involving 318
patients out of which 280 died [88%]) [2] in 1976. The
disease got its name from the Ebola River, which passes
near the Yambuku village where the outbreak first occurred
[3]. The first case of the current EVD outbreak in West
Africa was reported in Guinea in March 2014 [4], and from
there it spread across land borders to Liberia and Sierra
Leone, and to Senegal (by land travel) and Nigeria (by air
travel) [5,6]. The World Health Organization (WHO)
declared it a “Public Health Emergency of International* Correspondence: Haidergh@gmail.com
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unless otherwise stated.Concern” on August 7, 2014 [6]. Ebola virus disease has
an average case fatality rate of 50% [6]. As of February
4, 2015, a total of 22,500 confirmed, probable, and sus-
pected cases of EVD, and almost 9,000 deaths have been
reported [7]. A total of 132 new confirmed cases were
reported in the week ending to March 1 [8]. The case fa-
tality rate of the current outbreak in Guinea, Liberia and
Sierra Leoneis 76%; it is slightly less (61%) in hospitalized
patients [9]. Research has shown that EVD has mostly
affected economically deprived countries as limited re-
sources adversely affect a country’s infrastructure and ad-
ministration [10]. Probing into the factors that led to the
widespread outbreak, setting forth plans to counter EVD
cases in developing countries, and devising definitive mea-
sures to limit the spread of the disease are essential steps
that must be immediately taken (Figure 1).Review
We conducted a narrative clinical review on the epidemi-
ology, transmission, clinical manifestation, diagnosis, and
prevention of Ebola virus. We searched for online articles
using MEDLINE® and Google Scholar. The keywords/ral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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Figure 1 The 2014 Ebola outbreak in West Africa.
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Ebola virus disease”, “Mortality and morbidity associated
with Ebola virus disease”, “Pathogenesis of Ebola virus dis-
ease”, “Clinical manifestation of Ebola virus disease”, and
“Prevention of Ebola virus disease”. Articles dated from
1976 to 2015 were included in the study. Articles were
reviewed from November 2014 to March 2015. Search re-
sults yielded a total of 174 articles out of which 52 articles
were included in this study.
What is Ebola virus?
Ebola virus belongs to the family Filoviridae, which com-
promises three genera: Cuevavirus, Marburgvirus, and
Ebolavirus. This family belongs to the order Mononegavir-
ales. Five species of Ebola virus have been identified: Zaire,
Sudan, Bundibugyo, Reston, and Taï Forest. Bundibugyo
ebolavirus, Zaire ebolavirus, and Sudan ebolavirus have
been associated with large outbreaks in Africa. The current
West African outbreak was caused by Zaire ebolavirus,
which is also the most virulent among the five species.
Since 1976 it has caused multiple outbreaks in Central
Africa, with a mortality rate of 55%–88% [11-14]. The
Ebola virus genome contains a single strand of non-
segmented, negative-sense viral genomic RNA [15].How is Ebola virus transmitted?
Pteropodidae families of fruit bats are thought to be the
natural reservoirs of Ebola virus [16]. Humans can be in-
fected by Ebola virus by direct contact with blood and
body fluids of infected animals such as apes, gorillas,
fruit bats, and monkeys [6,17,18]. There is no evidence
that pet cat and dogs, mosquitoes, or other insects can
transmit Ebola virus [17]. Human-to-human transmis-
sion occurs via direct contact with the blood, organs,
secretion, and other bodily fluids (such as urine, feces,
semen, breast milk, mucus, vomit) of an infected person,
and via surface and materials contaminated with these
fluids [6,19-21]. Infected syringes and needles are other
ways by which the virus can be transmitted from an in-
fected human to uninfected humans [17]. The Ebola
virus does not spread through air or water [17]. Breaches
in infection control precautions have resulted in frequent
infections of health workers treating this outbreak. Direct
contact with the body of a deceased person during burial
ceremonies is another way by which Ebola virus can be
transmitted [22].
The Center for Disease Control and Prevention (CDC-
US) and the WHO have recommended that infected indi-
viduals should be quarantined for 21 days. The incubation
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studies have shown that Ebola virus transmission occurs
when there is a high viral load of bodily fluids [23]. The
person remains infectious as long as the virus is present in
their blood and bodily fluids. Patients who have com-
pletely recovered from the Ebola virus cannot spread it.
Ebola virus has been detected in semen of recovered pa-
tients, but it’s not known yet if it can spread through sex.
The WHO advises to abstain from sex or use condoms for
a period of three months after the patient is cured [6].
There is no evidence yet on when women recovering from
the Ebola virus can resume breastfeeding in [24].
What are the clinical symptoms of EVD?
The initial symptoms of EVD include fever, headache, fa-
tigue, sore throat, and muscle pain, which are followed by
anorexia, nausea, diarrhea, vomiting, rash, abdominal pain,
cough, shortness of breath, postural hypotension, edema,
headache, confusion, and coma [25]. In some cases, a
maculopapular rash develops after 5–7 days of symp-
toms [26]. In severe cases, the patient also develops
hemorrhagic complications (such as mucosal hemor-
rhages, nose bleeding, vomiting/coughing up blood, blood
in stool, petechiae, ecchymoses, uncontrollable bleeding
from venipuncture sites), severe metabolic disturbances,
convulsion, shock, and multiple organ failure. These com-
plications are the most common causes of death in pa-
tients [25]. Symptoms can appear anywhere between 2–21
days [27]. Gastrointestinal symptoms are the most com-
mon in the current outbreak [28].
How is EVD diagnosed?
Ebola virus usually reaches detectable levels in blood
after three days of symptoms [29]. A negative test before
this does not rule out EVD. IgM enzyme-linked immuno-
sorbent assay (ELISA), antigen-capture ELISA, polymerase
chain reaction (PCR), and virus isolation are the diagnos-
tic tests available to diagnose a patient who presents at a
health facility within a few days of showing symptoms
[29]. IgM and IgG antibodies are used for diagnosis later
in the disease course or after recovery. Laboratory findings
in EVD include Leukopenia, thrombocytopenia, and ele-
vated liver enzyme. Early and well-regulated inflammatory
response with elevated IL-6 concentration and IL-1beta
presence in a symptomatic patient is indicative of a good
outcome, while a defective innate immune reaction with
excessive macrophage/monocyte activation with release of
interleukin-10, absent antibody response and elevated
concentration of interleukin-1RA, and neopterin after a
few days of onset of disease is associated with a fatal
outcome [30]. According to one study, lymphoid deple-
tion and lymphopenia associated with Zaire ebolavirus
is most likely due to lymphocyte apoptosis via Fas/FasL
interaction [30]. The excessive macrophage/monocyteactivation leads to a “cytokine storm” triggering dissem-
inated intravascular coagulation, hypotension, and vas-
cular dysfunction, resulting in multiple organ failure,
vascular collapse, and shock [31]. According to a recent
study, elevated thrombomodulin and ferritin levels have
been associated with death and hemorrhage in Ebola
virus infected patients [32].
How to prevent the spread of EVD?
According to an estimate, 2–8 patients are exported
from the three major Ebola-inflicted countries in Africa
monthly, with 64% of the destinations being economically
deprived countries [33]. This poses (still unidentified)
problems for communities, which might get affected by
Muslims travelling from these countries for Hajj, the an-
nual Muslim pilgrimage to Mecca. Screening at all the ex-
port portals of the three afflicted countries would be the
most effective way of containing the outbreak. However,
implementing such screening protocols is beyond the abil-
ities of any individual country without international assist-
ance. One thing that can be implemented, however, is the
banning of all transportation from the affected countries,
not only via air travel but also via ships. A study in China
calculated the number of imported cases of EVD using
the basic reproductive number (R0) and found that early
interventions led to a substantial decrease in the preva-
lence and duration of the epidemic [34]. Hence, urgent
measures need to be taken so that all predominantly
Muslim countries are prepared to combat this epidemic.
According to the available data, barriers to prevent and
control the disease in affected countries include irresolute
and disorganized health systems, substandard sanitary con-
ditions, poor personal hygiene practices, and false beliefs
and stigma related to EVD [35]. There are further hin-
drances due to the unavailability of electricity, water, ad-
equate communication services between health officials,
and poor facilities for transportation of patients and speci-
mens [36]. The public health sector along with the respect-
ive chief authorities in developing countries must devise
strategies, keeping the available resources in mind, to deal
with the outbreak before it occurs.
As a first step, communities should be educated on
EVD’s symptoms, history, mode of transmission, and
methods of protection, including the importance of per-
sonal hygiene practices, via seminars, newspapers, and
other social media. A popular opinion leader (POL) giv-
ing this information would further help to remove the
misconception about the nature of the disease and indir-
ectly improve the quality of life of affected patients and
their families [37,38]. In addition, health systems should
formulate proper plans for emergency care, ensuring ad-
equate quarantine facilities, proper surveillance, case man-
agement, and contact tracing. Training should be given to
healthcare providers in areas such as prompt diagnosis
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wearing personal protective equipment, and safe burial
techniques [36]. There should be adequate distribution of
gloves, gowns, masks, soaps, and disinfectants to health-
care facilities, and safety precautions should be devised es-
pecially for laboratory personnel including pre-transfusion
testing [39]. The CDC guidelines for monitoring patients
(including symptomatic and asymptomatic), and precau-
tions for healthcare professionals (including wearing per-
sonal protective equipment, practicing personal hygiene,
use of disposable medical instruments, minimizing prick-
ing and aerosol producing procedures, monitoring ex-
posed staff, and adequate environment control) should be
practiced [40]. Special ambulances should be reserved to
enable the safe transport of EVD patients.
At state level, funds for proper sanitation, especially in
rural areas, should be reserved. Measures should be taken
to ensure the availability of water and electricity in all
areas. Internet and telephone services should be made
available round the clock in all hospitals and healthcare fa-
cilities for effective communication, and for reporting and
enrolling EVD cases. Home protective kits can further
enhance control measures, thus their distribution at
household-level should be considered [41].
Incident management systems (IMSs), such as the one
adopted by the CDC for the control of the current epi-
demic, have proven efficacious in preventing the spread
and adequately controlling the disease [42,43]. A report
about the employment of an IMS divulged that Nigeria
has successfully limited the outbreak and no further
cases have been reported since August 31, 2014 [43].
The employment of such a system has resulted in a de-
crease of EVD patients in Liberia [44]. Thus, an IMS
may be adopted and modified keeping in view the avail-
able resources and infrastructure of the respective coun-
try. The system involves authorizing representative health
personnel to fulfill specific tasks including international
correspondence, setting forth important measures to re-
spond to the event (including surveillance), supporting
affected families, devising plans to curtail chaos among
the public, and monitoring healthcare providers [41]. The
CDC also recommends limiting the movement of patients
(restriction of public transport especially aircrafts, ships,
trains, and buses), which states should implement if EVD
strikes their nation [45]. Rapid identification and treat-
ment of EVD-infected patients can significantly reduce
the possibility of secondary transmission [46].
Many drugs are being probed as preventive medications
for EVD, such as amiodarone, chloroquine, and clomi-
phene [37]. An effective vaccine is also being devised; re-
combinant vesicular stomatitis virus vaccine has been the
most promising, yet its efficacy has so far not been tested
in humans [47-50]. Another study found that virus-like
particles (VLPs) can provide post-exposure protection byamplifying Type 1 interferon signaling in macrophages
and dendritic cells, which are thought to be the initial
Ebola virus infection sites [51]. One study showed that
even if there was a vaccine, when the nature of the disease
is considered, vaccination wouldn’t be efficacious and
cost-effective in controlling the current outbreak, and
would divert the attention of health authorities from
proven effective control measures [52]. However, vac-
cination can reduce case fatality and prevent further
outbreaks. Another problem is that Ebola virus mostly
affects low-income countries, which might not have
enough resources to develop a vaccine. However, as EVD
is considered a weapon of bioterrorism, this may drive the
developed world to work out a definitive and safe vaccine
soon enough. Until then, countries should concentrate on
early detection, isolation, prompt treatment, contact tra-
cing, and proper burials.
Conclusion
The public health sector along with the respective chief
authorities in developing countries must devise strat-
egies, keeping the available resources in mind, to deal
with the outbreak before it occurs.
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